SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (173)3/3/2002 12:31:03 PM
From: sso  Read Replies (1) | Respond to of 508
 
Irwin,

Infergen may be great, but Oritavancin(sp) is GOING to be huge. I hear Lilly is kicking themselves over that one.



To: IRWIN JAMES FRANKEL who wrote (173)3/4/2002 5:51:37 PM
From: Biomaven  Read Replies (2) | Respond to of 508
 
IJ,

Well if they do add another candidate to their portfolio I hope that they pick one that at least fits with their existing pipeline. Right now their pipe makes no sense from a sales and marketing perspective.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News